By mathematically describing early hepatitis C virus (HCV) RNA decay after initiation of
interferon (IFN)‐based antiviral therapy, crucial parameters of the in vivo viral kinetics have …

Chronic infection with HCV has an estimated prevalence of 1.6–2.0% worldwide and is a
major cause of liver-related death. The first attempts to halt the progression of infection relied …

We disclose here a series of P4-benzoxaborole-substituted macrocyclic HCV protease
inhibitors. These inhibitors are potent against HCV NS3 protease, their anti-HCV replicon …

Background/aims: Chronic hepatitis C virus infection (HCV) is a major comorbidity in
patients with haemophilia. Peginterferon alpha and ribavirin is current standard anti‐HCV …

Since 1986, interferon‐alfa (IFN‐α) monotherapy has been administered for patients with
chronic hepatitis C (CHC). However, sustained response rate is only about 8% to 9 …

More than 3.2 million people in the United States and more than 200 million people
worldwide are chronically infected with hepatitis C virus (HCV) and are at risk for the …

Background: The standard treatments for chronic infection with the hepatitis C virus (HCV)
are peginterferon α-2a or α-2b plus ribavirin, but it remains unclear if one has a better …

We read with great interest the article by Cavazza et al., 1 who demonstrated that an
advanced histological stage was the only risk factor associated with the development of …

Purpose Reported sustained virological response (SVR) rates in Asians with chronic
hepatitis C (CHC) exceed those of other ethnic groups, but differences in body weight across …

Chronic hepatitis C is a common cause of liver disease worldwide. It is a slow and
progressive condition which can lead to decompensated cirrhosis and hepatocellular …